U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 4 of 4 results

Status:
Designated

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
US Approved Rx (2019)
First approved in 2004

Class:
PROTEIN

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Tasisulam sodium, previously known as LY573636, were initially recognized by Eli Lilly for their significant antiproliferative activities in solid tumor cell lines, but their mechanism of action was unknown. Subsequent studies have revealed that LY57...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Retaspimycin (IPI-504) was previously under development by manufacturer Infinity Pharmaceuticals in conjunction with MedImmune, a part of AstraZeneca. Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative ...